Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashley Dumas

Child & Adolescent Psychiatry Little Rock, AR Medical Doctor

NPI 1285993295 CMS profile 1387132

1 Childrens Way # 653, Little Rock, AR 72202

Open in the dashboard

General payments

$7,163

377 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Dumas of Little Rock, AR is reported in the CMS Open Payments database as having received $7,163 across 377 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,305 66
2024 General $1,726 85
2023 General $2,126 112
2022 General $976 59
2021 General $738 40
2020 General $260 13
2019 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Dumas
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Ashley Dumas were reported at $1,305. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Ashley Dumas Child & Adolescent Psychiatry median Middle half National median
2019 $32 $129 $42–$419 $163
2020 $260 $81 $28–$226 $114
2021 $738 $115 $31–$326 $132
2022 $976 $124 $40–$382 $149
2023 $2,126 $130 $45–$420 $160
2024 $1,726 $141 $42–$490 $164
2025 $1,305 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $916 44 payments
  2. ITI, Inc. $774 37 payments
  3. Corium, Inc. $748 37 payments
  4. Teva Pharmaceuticals USA, Inc. $703 41 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $643 33 payments
  6. Alkermes, Inc. $551 32 payments
  7. Lundbeck LLC $531 23 payments
  8. Supernus Pharmaceuticals, Inc. $433 34 payments
  9. Otsuka America Pharmaceutical, Inc. $332 16 payments
  10. Axsome Therapeutics, Inc. $325 16 payments
  11. Other $1,206 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,163 377 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $785 36 payments
  2. Azstarys $748 37 payments
  3. CAPLYTA $690 33 payments
  4. ABILIFY MAINTENA $546 26 payments
  5. ARISTADA Cns $506 30 payments
  6. ARISTADA Cns $506 30 payments
  7. TRINTELLIX $453 25 payments
  8. LYBALVI $450 26 payments
  9. ARISTADA Cns $389 23 payments
  10. ARISTADA Cns $389 23 payments
  11. Other $4,520 244 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

377 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record